Search

Your search keyword '"Gazdar, A. F."' showing total 2,177 results

Search Constraints

Start Over You searched for: Author "Gazdar, A. F." Remove constraint Author: "Gazdar, A. F."
2,177 results on '"Gazdar, A. F."'

Search Results

1. A biobank of small cell lung cancer CDX models elucidates inter- and intratumoral phenotypic heterogeneity

2. Cell-autonomous immune gene expression is repressed in pulmonary neuroendocrine cells and small cell lung cancer

7. Taxane-Platin-Resistant Lung Cancers Co-develop Hypersensitivity to JumonjiC Demethylase Inhibitors

9. Characterization of Human Cancer Cell Lines by Reverse-phase Protein Arrays

10. MYC Drives Progression of Small Cell Lung Cancer to a Variant Neuroendocrine Subtype with Vulnerability to Aurora Kinase Inhibition

11. Treatment and prevention of intraepithelial neoplasia: an important target for accelerated new agent development.

15. Small Cell Lung Cancer: Can Recent Advances in Biology and Molecular Biology Be Translated into Improved Outcomes?

21. Supplementary Figures 1-4 from Knockdown of Oncogenic KRAS in Non–Small Cell Lung Cancers Suppresses Tumor Growth and Sensitizes Tumor Cells to Targeted Therapy

22. Data from Knockdown of Oncogenic KRAS in Non–Small Cell Lung Cancers Suppresses Tumor Growth and Sensitizes Tumor Cells to Targeted Therapy

23. Supplementary Tables 1-2 from Knockdown of Oncogenic KRAS in Non–Small Cell Lung Cancers Suppresses Tumor Growth and Sensitizes Tumor Cells to Targeted Therapy

25. Supplementary Table 3 from Knockdown of Oncogenic KRAS in Non–Small Cell Lung Cancers Suppresses Tumor Growth and Sensitizes Tumor Cells to Targeted Therapy

26. Data from Human Lung Epithelial Cells Progressed to Malignancy through Specific Oncogenic Manipulations

27. Supplementary Methods, Tables 1 - 4, Figures 1 - 7 from Human Lung Epithelial Cells Progressed to Malignancy through Specific Oncogenic Manipulations

29. Supplementary Methods from Knockdown of Oncogenic KRAS in Non–Small Cell Lung Cancers Suppresses Tumor Growth and Sensitizes Tumor Cells to Targeted Therapy

30. Supplementary Figure Legends 1-4 from Knockdown of Oncogenic KRAS in Non–Small Cell Lung Cancers Suppresses Tumor Growth and Sensitizes Tumor Cells to Targeted Therapy

33. Supplementary Material from An Expression Signature as an Aid to the Histologic Classification of Non–Small Cell Lung Cancer

35. Data from Abnormalities of the TITF-1 Lineage-Specific Oncogene in NSCLC: Implications in Lung Cancer Pathogenesis and Prognosis

36. Supplementary Methods, Figures 1 - 7, and Tables 1 - 6 from Radiation-Enhanced Lung Cancer Progression in a Transgenic Mouse Model of Lung Cancer Is Predictive of Outcomes in Human Lung and Breast Cancer

40. Supplementary Data from Abnormalities of the TITF-1 Lineage-Specific Oncogene in NSCLC: Implications in Lung Cancer Pathogenesis and Prognosis

41. Supplementary Figure 4 from Acquired Resistance to EGFR Inhibitors Is Associated with a Manifestation of Stem Cell–like Properties in Cancer Cells

42. Data Supplement from A Search for Novel Cancer/Testis Antigens in Lung Cancer Identifies VCX/Y Genes, Expanding the Repertoire of Potential Immunotherapeutic Targets

43. Data from PIK3CA Mutations and Copy Number Gains in Human Lung Cancers

44. Supplementary Table S2 from Molecular Portraits of Epithelial, Mesenchymal, and Hybrid States in Lung Adenocarcinoma and Their Relevance to Survival

45. Data from A Search for Novel Cancer/Testis Antigens in Lung Cancer Identifies VCX/Y Genes, Expanding the Repertoire of Potential Immunotherapeutic Targets

47. Supplementary Table 2 from Acquired Resistance to EGFR Inhibitors Is Associated with a Manifestation of Stem Cell–like Properties in Cancer Cells

48. Supplementary Figure 2 from Acquired Resistance to EGFR Inhibitors Is Associated with a Manifestation of Stem Cell–like Properties in Cancer Cells

50. Supplementary Figure 1 from PIK3CA Mutations and Copy Number Gains in Human Lung Cancers

Catalog

Books, media, physical & digital resources